Prospective subgroup analyses of the randomized MCL‐002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma

In the mantle cell lymphoma (MCL)‐002 study, lenalidomide demonstrated significantly improved median progression‐free survival (PFS) compared with investigator's choice (IC) in patients with relapsed/refractory MCL. Here we present the long‐term follow‐up data and results of preplanned subgroup...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcaini, Luca, Lamy, Thierry, Walewski, Jan, Belada, David, Mayer, Jiri, Radford, John, Jurczak, Wojciech, Morschhauser, Franck, Alexeeva, Julia, Rule, Simon, Cabeçadas, José, Campo, Elias, Pileri, Stefano A., Biyukov, Tsvetan, Patturajan, Meera, Casadebaig Bravo, Marie‐Laure, Trnĕný, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814930/
https://www.ncbi.nlm.nih.gov/pubmed/29193019
http://dx.doi.org/10.1111/bjh.15025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814930/
https://www.ncbi.nlm.nih.gov/pubmed/29193019
http://dx.doi.org/10.1111/bjh.15025

Ejemplares similares